G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner

Molecular Cancer Therapeutics

Volumn 2, Issue 10, 2003, Pages 1031-1043

  Lai, Johnathan C ^a,b   Benimetskaya, Luba ^a   Santella, Regina M ^c   Wang, Qiao ^c   Miller, Paul S ^d   Stein, C A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Johns Hopkins University ^*  (United States)

^c NONE   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTISENSE OLIGONUCLEOTIDE; BROXURIDINE; COLORING AGENT; DNA; ENZYME INHIBITOR; GUANOSINE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOTIDE; OBLIMERSEN; OLIGONUCLEOTIDE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL MEMBRANE; CELL MEMBRANE POTENTIAL; CHEMISTRY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; MALE; METABOLISM; MITOCHONDRION; MUTATION; NORTHERN BLOTTING; PROSTATE TUMOR; PROTEIN MOTIF; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

AGAR; AMINO ACID MOTIFS; ANNEXIN A5; BLOTTING, NORTHERN; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; COLORING AGENTS; CPG ISLANDS; DNA; DNA METHYLATION; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; G1 PHASE; GUANOSINE; HUMANS; MALE; MEMBRANE POTENTIALS; MITOCHONDRIA; MUTATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; S PHASE; THIONUCLEOTIDES; TIME FACTORS; TRANSFECTION;

EID: 1042275580     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994. (Pubitemid 24054605)
2. Reed, J. C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. Am., 9: 451-473, 1995.
3. Reed, J. C., Jurgensmeier, J. M., and Matsuyama, S. Bcl-2 family proteins and mitochondria. Biochim. Biophys. Acta, 1366: 127-137, 1998. (Pubitemid 28467027)
4. Hockenberry, D., Nunez, G., Milliman, C., Schreiber, R., and Krosmeyer, S. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334, 1990.
5. Krajewski, S., Tanaka, S., and Takayama, S. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes. Cancer Res., 53: 4701, 1993.
6. De Jong, D., Prins, F., and Mason, D. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res., 54: 256-260, 1994. (Pubitemid 24042119)
7. Zhu, W., Cowie, A., and Wasfy, G. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. EMBO J., 15: 4130, 1996.
8. Schlesinger, P., Gross, A., and Yin, X. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc. Natl. Acad. Sci. USA, 94: 11357, 1997.
9. Vander Heiden, M., Chandel, N., Schumacker, P., and Thompson, C. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol. Cell, 3: 159-167, 1999. (Pubitemid 29292617)
10. Hockenberry, D., Oltvai, Z., Yin, X., Milliman, C., and Krosmeyer, S. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251, 1993. (Pubitemid 23320288)
11. Zhong, L., Sarafian, T., Kane, D., Charles, A., Mah, S., Edwards, R., and Bredesen, D. Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc. Natl. Acad. Sci. USA, 90: 4533-4537, 1993. (Pubitemid 23148939)
12. Kane, D., Sarafian, T., Anton, R., Hahn, H., Gralla, E., Valentine, J., Ord, T., and Bredesen, D. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science, 262: 1274-1277, 1993. (Pubitemid 24036095)
13. Miyashita, T. and Reed, R. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993. (Pubitemid 23013689)
14. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenberry, D., Korsmeyer S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and campothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993. (Pubitemid 23127114)
15. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res., 53: 4251-4256, 1993. (Pubitemid 24146774)
16. Tang, C., Willingham, M. C., Reed, J. C., Miyashita, T., Ray, S., Ponnathpur, V., Huang, Y., Mahoney, M. E., Bullock, G., and Bhalla, K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia, 8: 1960-1969, 1994.
17. Teixeira, C., Reed, J. C., and Pratt, M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
18. Pratt, M. A., Krajewski, S., Menard, M., Krajewski, M., Macleod, H., and Reed, J. C. Estrogen withdrawal-induced human breast cancer tumor regression in nude mice is prevented by Bcl-2. FEBS Lett., 440: 403-408, 1998. (Pubitemid 29052323)
19. Dorai, T., Perlman, H., Walsh, K., Shabsigh, A., Golubof, E. T., Olsson, C. A., and Buttyan, R. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int. J. Cancer, 82: 846-852, 1999. (Pubitemid 29384336)
20. Jansen, B., Schalgbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H.G., and Pehamberger, H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998. (Pubitemid 28137379)
21. Jansen, B., Wacheck, V., Heere-Ress, E., Schalgbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., and Pehamberger, H. Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet, 356: 1728-1733, 2000.
22. Kitada, S., Miyashita, T., Tanaka, S., and Reed, J. C. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev., 3: 157-169, 1993. (Pubitemid 23243676)
23. Stein, C. A. and Cheng, Y. C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science, 261: 1004-1012, 1993. (Pubitemid 23300859)
24. Dias, N. and Stein, CA. The use of antisense oligonucleotides to validate gene function. Mol. Cancer Ther., 1: 347-355, 2001.
25. Chi, K., Wallis, A. E., Lee, C. H., De Menezes, D. L., Sartor, J., Dragowska, W. H., and Mayer, L. D. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res. Treat., 63: 199-212, 2000.
26. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S., Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S., and Saya, H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933-943, 1998. (Pubitemid 28102597)
27. Miyake, H., Tolcher, A., and Gleave, M. E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J. Natl. Cancer Inst., 92: 34-41, 2000. (Pubitemid 30082226)
28. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem., 270: 2620-2627, 1995.
29. Khaled, Z., Benimetskaya, L., Zeltser, R., Khan, T., Sharma, H. W., Narayanan, R., and Stein, C. A. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res., 24: 737-745, 1996.
30. Benimetskaya, L., Miller, P., Benimetsky, S., Maciaszek, A., Guga, P., Beaucage, S. L., Wilk, A., Grajkowski, A., Halperin, A. L., and Stein, C. A. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-α (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligonucleotides: relationship to the decreased viability of T24 Bladder and PC3 prostate cancer cells. Mol. Pharmacol., 60: 1296-1307, 2001. (Pubitemid 33144901)
31. Tarpey, M. M. and Fridovich, I. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ. Res., 89: 224-236, 2001. (Pubitemid 34133992)
32. Yarborough, A., Zhang, Y. J., Hsu, T. M., and Santella, R. M. Immunoperoxidase detection of 8-hydroxydeoxyguanosine in aflatoxin B1 treated rat liver and human oral mucosal cells. Cancer Res., 56: 683-688, 1996.
33. Pani, G., Colavitti, R., Bedogni, B., Anzevino, R., Borrelo, S., and Galeotti, T. A redox signaling mechanism for density-dependent inhibition of cell growth. J. Biol. Chem., 275: 38891-38899, 2000. (Pubitemid 32010745)
34. 1-S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb . Science, 245: 180-183, 1989.
35. Simbulan-Rosenthal, C. M., Rosenthal, D. S., Luo, R., and Smulson, M. E. Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol a expression during early S phase, Oncogene. 18: 5015-5023, 1999. (Pubitemid 29443747)
36. Hartman, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., and Kreig, A. M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo . J. Immunol., 164: 1617-1624, 2000. (Pubitemid 30067282)